Travis Eason v. HHS - Influenza, Guillain-Barré Syndrome (2022)
Case summary [AI summaries can sometimes make mistakes]
On March 19, 2018, Travis Eason filed a petition for compensation under the National Vaccine Injury Compensation Program, alleging Guillain-Barré Syndrome (GBS) resulted from an influenza vaccine administered on September 12, 2012. The respondent argued the petition was barred by the statute of limitations and that Mr.
Eason's condition was multiple sclerosis (MS), not GBS. The core issue was whether Mr.
Eason met the Vaccine Injury Table criteria for GBS. Petitioner's counsel was Milton Clay Ragsdale, and respondent's counsel was Colleen Clemons Hartley.
Special Master Nora Beth Dorsey presided over the case. Mr.
Eason, 49 years old at the time of vaccination, had a significant past medical history including hypertension, obesity, type II diabetes mellitus, Charcot foot disease, myocardial infarction, coronary stent placement, obstructive sleep apnea, and toe amputations. He had been diagnosed with diabetic peripheral neuropathy in 2010.
On September 12, 2012, he received an influenza vaccine. Approximately 18 days later, on September 30, 2012, he reported experiencing leg weakness and numbness, which progressed rapidly.
He sought medical attention, and initial diagnoses included lumbar strain and upper respiratory infection. However, by October 1, 2012, he reported sudden onset numbness from the waist down and difficulty walking.
Neurological examinations revealed weakness and altered sensation below the waist. Initial concerns included spinal cord compression or infarction.
Electromyography/nerve conduction velocity (EMG/NCV) testing on October 8, 2012, indicated a severe diffuse sensorimotor peripheral neuropathy compatible with GBS. A lumbar puncture showed elevated protein.
Dr. Keith A.
Thompson diagnosed acute onset GBS with paralysis up to T10 and initiated intravenous immunoglobulin (IVIG) treatment. Over the following years, Mr.
Eason continued to receive IVIG treatments, with his condition fluctuating but generally improving from his nadir of paralysis. His treating physicians, including Dr.
Larry W. Epperson and Dr.
Shin Oh, consistently diagnosed him with GBS, with Dr. Oh also noting an atypical GBS with transverse myelopathy overlap.
Dr. Epperson's diagnoses included GBS, and at times, GBS versus Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
None of his treating physicians diagnosed him with Multiple Sclerosis (MS). Respondent's expert, Dr.
Peter D. Donofrio, opined that Mr.
Eason's presentation was more consistent with MS, citing brain MRI findings, visual evoked potentials, and the presence of bladder/bowel dysfunction at onset. He also argued that the chronic use of IVIG and improvement over time were inconsistent with GBS, suggesting CIDP or another disorder.
Dr. Donofrio also questioned the GBS diagnosis due to the absence of upper extremity weakness and the presence of bladder incontinence at onset, and suggested EMG/NCV findings could be explained by severe diabetic polyneuropathy.
Special Master Dorsey reviewed the extensive medical records and expert reports. She found that Mr.
Eason's treating physicians consistently diagnosed him with GBS after appropriate diagnostic testing. She determined that Mr.
Eason met the five criteria for a Table GBS claim: bilateral flaccid limb weakness and decreased reflexes, a monophasic illness pattern, an onset-to-nadir interval between 12 hours and 28 days (approximately 21 days), subsequent clinical plateau with improvement without significant relapse, and the absence of a more likely alternative diagnosis. The Special Master found that while alternative diagnoses like MS and CIDP were considered, they were not supported by the evidence, particularly the negative oligoclonal bands and the lack of MS-specific MRI findings.
She also found that Mr. Eason's onset of symptoms (18-19 days post-vaccination) fell within the 3-42 day window for GBS following an influenza vaccine.
The Special Master also addressed the statute of limitations, finding that the petition was timely filed under the Vaccine Act's lookback provision due to the March 21, 2017, revision of the Vaccine Injury Table to include GBS following flu vaccination. The Special Master granted Mr.
Eason's motion for a ruling on the record, finding him entitled to compensation. A separate order for damages was to be issued.
Theory of causation
Travis Eason, a 49-year-old male, received an influenza vaccine on September 12, 2012. He developed symptoms of Guillain-Barré Syndrome (GBS) approximately 18-19 days later, on September 30 or October 1, 2012, with progressive weakness and numbness in his lower extremities, progressing to paralysis up to T10. His treating physicians, including Dr. Epperson and Dr. Oh, diagnosed him with GBS, with Dr. Oh also noting an atypical GBS with transverse myelopathy overlap. The respondent argued that Mr. Eason's condition was multiple sclerosis (MS) and not GBS, and that his claim was time-barred. The court reviewed extensive medical records and expert reports from petitioner's expert, Dr. Shin Oh, and respondent's expert, Dr. Peter D. Donofrio. The court found that Mr. Eason's medical history, diagnostic tests including EMG/NCV studies and CSF analysis, and the opinions of his treating physicians supported a diagnosis of GBS. The court also found that his onset of symptoms fell within the Vaccine Injury Table's criteria for GBS following an influenza vaccine (onset 18-19 days post-vaccination, within the 3-42 day window). The court ruled that Mr. Eason met the Table criteria for GBS, including bilateral flaccid limb weakness, a monophasic illness pattern, an onset-to-nadir interval of approximately 21 days, subsequent clinical plateau with improvement without significant relapse, and the absence of a more likely alternative diagnosis (MS and CIDP were ruled out). The court also found the petition timely filed under the § 16(b) lookback provision due to the March 21, 2017, revision of the Vaccine Injury Table. The court ruled that Mr. Eason met the Table criteria for GBS and was entitled to compensation, granting his motion for a ruling on the record. A separate order for damages will be issued. Attorneys: Milton Clay Ragsdale for petitioner; Colleen Clemons Hartley for respondent. Special Master: Nora Beth Dorsey. Decision Date: March 30, 2022.
Source PDFs
USCOURTS-cofc-1_18-vv-00406